Raily Aesthetic Medicine International Holdings Ltd. said it expects to narrow its full-year loss for the year ended 31 December 2025 to about RMB2 million, from a loss of about RMB63 million in 2024. It also forecasts a return to profit attributable to owners of the parent of around RMB2 million, versus a loss of about RMB59 million a year earlier, mainly due to the absence of a one-off impairment loss recorded in 2024 and improved overall profit margins.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raily Aesthetic Medicine International Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260304-12041061), on March 04, 2026, and is solely responsible for the information contained therein.